Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Happy New Year, biotech ...

Sumitomo Pharma's Gemtesa (vibegron) has been approved by the U.S. Food and Drug Administration for men with overactive ...

Researchers have applied AI to every step of the drug development process. But this might not be enough to design safe and ...

After years of controversy, stem cells are on the cusp of cures for conditions like epilepsy and type 1 diabetes.

Discover why psychiatrists are moving beyond single-treatment approaches and how combining therapies could be the key to ...

The upside in Precigen's stock comes after it completes the rolling submission of an FDA filing for its first potentially marketed product.

When compared to the broader market, Verastem Oncology has shown exceptional performance. The company’s stock has surged 30.57% year-to-date, a stark contrast to the S&P 500’s meager performance of -0 ...

Verastem's pipeline's emphasis is on RAS/MAPK-driven tumors, so the FDA's ruling might have a major influence on their ...

The analyst remains optimistic about AXS-05's approval, highlighting that the FDA's continued designation of AXS-05 as a ...

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, ...

The most-read stories published by Multiple Sclerosis News Today in 2024 focused on living with MS and news on disease risk ...

We recently published a list of the 12 Best Biotech Penny Stocks To Invest In Now. In this article, we are going to take a ...